Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?

Journal of Autoimmunity

Volumn 75, Issue , 2016, Pages 1-5

  Meroni, Pier Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Antimalarials; Antiphospholipid syndrome; Hydroxychloroquine; Miscarriages

Indexed keywords

HYDROXYCHLOROQUINE; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HIGH RISK PREGNANCY; HUMAN; IMMUNOMODULATION; INTRAUTERINE GROWTH RETARDATION; MULTICENTER STUDY (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; PREGNANCY COMPLICATION; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; RISK ASSESSMENT; SPONTANEOUS ABORTION; THROMBOSIS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; TREATMENT OUTCOME; TROPHOBLAST;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; HYDROXYCHLOROQUINE; PREGNANCY; PREGNANCY COMPLICATIONS; TREATMENT OUTCOME; TROPHOBLASTS;

EID: 84995578428     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.07.003     Document Type: Review

References (51)

1. [1] Wallace, D.J., The evolution of drug discovery in systemic lupus erythematosus. Nat. Rev. Rheumatol. 11 (2015), 616–620.
2. [2] Gomez-Puerta, J.A., Cervera, R., Diagnosis and classification of the antiphospholipid syndrome. J. Autoimmun. 48–49 (2014), 20–25.
3. [3] Huchon, C., Deffieux, X., Beucher, G., Capmas, P., Carcopino, X., Costedoat-Chalumeau, N., Delabaere, A., et al. Pregnancy loss: French clinical practice guidelines. Eur. J. Obstet. Gynecol. Reprod. Biol. 201 (2016), 18–26.
4. [4] Katzav, A., Menachem, A., Maggio, N., Pollak, L., Pick, C.G., Chapman, J., IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome. J. Autoimmun. 55 (2014), 86–93.
5. [5] Legault, K.J., Ugarte, A., Crowther, M.A., Ruiz-Irastorza, G., Prevention of recurrent thrombosis in antiphospholipid syndrome: different from the general population?. Curr. Rheumatol. Rep., 18, 2016, 26.
6. [6] Yalavarthi, S., Gould, T.J., Rao, A.N., Mazza, L.F., Morris, A.E., Nunez-Alvarez, C., Hernandez-Ramirez, D., et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 67 (2015), 2990–3003.
7. [7] Hoayek, J.G., Moussa, H.N., Rehman, H.A., Nasab, S.H., Blackwell, S.C., Sibai, B.M., Catastrophic antiphospholipid syndrome in pregnancy, a diagnosis that should not be missed. J. Matern. Fetal Neonatal Med., 2016, 1–6.
8. [8] Zandman-Goddard, G., Pierangeli, S.S., Gertel, S., Blank, M., Tolerogenic dendritic cells specific for beta2-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome. J. Autoimmun. 54 (2014), 72–80.
9. [9] Tanimura, K., Jin, H., Suenaga, T., Morikami, S., Arase, N., Kishida, K., Hirayasu, K., et al. beta2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Blood 125 (2015), 2835–2844.
10. [10] Gerosa, M., Meroni, P.L., Erkan, D., Recognition and management of antiphospholipid syndrome. Curr. Opin. Rheumatol. 28 (2016), 51–59.
11. [11] Chighizola, C.B., Raschi, E., Borghi, M.O., Meroni, P.L., Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr. Opin. Rheumatol. 27 (2015), 476–482.
12. [12] Rainsford, K.D., Parke, A.L., Clifford-Rashotte, M., Kean, W.F., Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23 (2015), 231–269.
13. [13] Edwards, M.H., Pierangeli, S., Liu, X., Barker, J.H., Anderson, G., Harris, E.N., Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 (1997), 4380–4384.
14. [14] Espinosa, R.G., Pierangeli, S.S., Gharavi, A.E., Harris, E.N., Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost. 87 (2002), 518–522.
15. [15] Bertolaccini, M.L., Contento, G., Lennen, R., Sanna, G., Blower, P.J., Ma, M.T., Sunassee, K., Girardi, G., Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J. Autoimmun. 75 (2016), 30–38, 10.1016/j.jaut.2016.04.008 pii: S0896-8411(16)30040-3.
16. [16] Meroni, P.L., Borghi, M.O., Raschi, E., Tedesco, F., Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 7 (2011), 330–339.
17. [17] Chighizola, C.B., Gerosa, M., Trespidi, L., Di Giacomo, A., Rossi, F., Acaia, B., Meroni, P.L., Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Rev. Clin. Immunol. 10 (2014), 1505–1517.
18. [18] Andreoli, L., Chighizola, C.B., Nalli, C., Gerosa, M., Borghi, M.O., Pregnolato, F., Grossi, C., et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol. 67 (2015), 2196–2204.
19. [19] Pengo, V., Ruffatti, A., Tonello, M., Cuffaro, S., Banzato, A., Bison, E., Denas, G., et al. Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J. Thromb. Haemost. 13 (2015), 782–787.
20. [20] Clark, C.A., Spitzer, K.A., Laskin, C.A., Obstetric antiphospholipid syndrome: has the black swan swallowed a red herring?. J. Rheumatol. 42 (2015), 155–157.
21. [21] Arachchillage, D.R., Machin, S.J., Mackie, I.J., Cohen, H., Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb. Haemost. 113 (2015), 13–19.
22. [22] Meroni, P.L., Chighizola, C.B., Gerosa, M., Trespidi, L., Acaia, B., Obstetric antiphospholipid syndrome: lobsters only? or should we also look for selected red herrings?. J. Rheumatol. 42 (2015), 158–160.
23. [23] Alijotas-Reig, J., Ferrer-Oliveras, R., Ruffatti, A., Tincani, A., Lefkou, E., Bertero, M.T., Coloma-Bazan, E., et al. The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun. Rev. 14 (2015), 387–395.
24. [24] Bouvier, S., Cochery-Nouvellon, E., Lavigne-Lissalde, G., Mercier, E., Marchetti, T., Balducchi, J.P., Mares, P., et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 123 (2014), 404–413.
25. [25] Ruffatti, A., Salvan, E., Del Ross, T., Gerosa, M., Andreoli, L., Maina, A., Alijotas-Reig, J., et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb. Haemost. 112 (2014), 727–735.
26. [26] Watanabe, N., Yamaguchi, K., Motomura, K., Hisano, M., Sago, H., Murashima, A., Combination therapy with anticoagulants, corticosteroids and intravenous immunoglobulin for women with severe obstetric antiphospholipid syndrome. Clin. Exp. Rheumatol. 32 (2014), 299–300.
27. [27] Mekinian, A., Lazzaroni, M.G., Kuzenko, A., Alijotas-Reig, J., Ruffatti, A., Levy, P., Canti, V., et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun. Rev. 14 (2015), 498–502.
28. [28] Sciascia, S., Hunt, B.J., Talavera-Garcia, E., Lliso, G., Khamashta, M.A., Cuadrado, M.J., The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 214:273 (2016), e271–278.
29. [29] Parke, A.L., Antimalarial drugs, pregnancy and lactation. Lupus 2:Suppl 1 (1993), S21–S23.
30. [30] Borden, M.B., Parke, A.L., Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf. 24 (2001), 1055–1063.
31. [31] Costedoat-Chalumeau, N., Amoura, Z., Duhaut, P., Huong, D.L., Sebbough, D., Wechsler, B., Vauthier, D., et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 48 (2003), 3207–3211.
32. [32] Sammaritano, L.R., Bermas, B.L., Rheumatoid arthritis medications and lactation. Curr. Opin. Rheumatol. 26 (2014), 354–360.
33. [33] Kaplan, Y.C., Ozsarfati, J., Nickel, C., Koren, G., Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 81 (2016), 835–848.
34. [34] Costedoat-Chalumeau, N., Amoura, Z., Aymard, G., Le, T.H., Wechsler, B., Vauthier, D., Dermer, M.E., et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 46 (2002), 1123–1124.
35. [35] Gotestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., da Silva, J., et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheum. Dis. 75 (2016), 795–810.
36. [36] Tett, S., Day, R., Cutler, D., Hydroxychloroquine relative bioavailability: within subject reproducibility. Br. J. Clin. Pharmacol. 41 (1996), 244–246.
37. [37] Tett, S.E., Cutler, D.J., Beck, C., Day, R.O., Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis–a prospective, dose ranging study. J. Rheumatol. 27 (2000), 1656–1660.
38. [38] Munster, T., Gibbs, J.P., Shen, D., Baethge, B.A., Botstein, G.R., Caldwell, J., Dietz, F., et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 46 (2002), 1460–1469.
39. [39] Costedoat-Chalumeau, N., Amoura, Z., Hulot, J.S., Hammoud, H.A., Aymard, G., Cacoub, P., Frances, C., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54 (2006), 3284–3290.
40. [40] Jallouli, M., Galicier, L., Zahr, N., Aumaitre, O., Frances, C., Le Guern, V., Liote, F., et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 67 (2015), 2176–2184.
41. [41] Lee, J.Y., Vinayagamoorthy, N., Han, K., Kwok, S.K., Ju, J.H., Park, K.S., Jung, S.H., et al. Association of polymorphisms of Cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus Erythematosus. Arthritis Rheumatol. 68 (2016), 184–190.
42. [42] Costedoat-Chalumeau, N., Galicier, L., Aumaitre, O., Frances, C., Le Guern, V., Liote, F., Smail, A., et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann. Rheum. Dis. 72 (2013), 1786–1792.
43. [43] Mar, N., Kosowicz, R., Hook, K., Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss. J. Thromb. Thrombolysis 38 (2014), 196–200.
44. [44] Buchanan, N.M., Toubi, E., Khamashta, M.A., Lima, F., Kerslake, S., Hughes, G.R., Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann. Rheum. Dis. 55 (1996), 486–488.
45. [45] Sciascia, S., Branch, D.W., Levy, R.A., Middeldorp, S., Pavord, S., Roccatello, D., Ruiz-Irastorza, G., et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb. Haemost. 115 (2016), 285–290.
46. [46] Leroux, M., Desveaux, C., Parcevaux, M., Julliac, B., Gouyon, J.B., Dallay, D., Pellegrin, J.L., et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 24 (2015), 1384–1391.
47. [47] Rand, J.H., Wu, X.X., Quinn, A.S., Ashton, A.W., Chen, P.P., Hathcock, J.J., Andree, H.A., et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115 (2010), 2292–2299.
48. [48] Tong, M., Viall, C.A., Chamley, L.W., Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum. Reprod. Update 21 (2015), 97–118.
49. [49] Albert, C.R., Schlesinger, W.J., Viall, C.A., Mulla, M.J., Brosens, J.J., Chamley, L.W., Abrahams, V.M., Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am. J. Reprod. Immunol. 71 (2014), 154–164.
50. [50] Marchetti, T., Ruffatti, A., Wuillemin, C., de Moerloose, P., Cohen, M., Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J. Thromb. Haemost. 12 (2014), 910–920.
51. [51] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derksen, R.H., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4 (2006), 295–306.